Edition:
India

Abbott Laboratories (ABT.N)

ABT.N on New York Stock Exchange

107.90USD
4 Dec 2020
Change (% chg)

$0.37 (+0.34%)
Prev Close
$107.53
Open
$107.10
Day's High
$108.27
Day's Low
$106.93
Volume
1,206,750
Avg. Vol
1,357,011
52-wk High
$115.14
52-wk Low
$61.62

Latest Key Developments (Source: Significant Developments)

Abbott Laboratories Launches First Infant Formula In Canada With An Ingredient Identical In Structure To Immune Component Found In Breast Milk
Tuesday, 17 Nov 2020 

Nov 17 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - LAUNCHES FIRST INFANT FORMULA IN CANADA WITH AN INGREDIENT IDENTICAL IN STRUCTURE TO IMMUNE COMPONENT FOUND IN BREAST MILK.  Full Article

Abbott Secures CE Mark For Next-Generation Freestyle Libre 3 System
Monday, 28 Sep 2020 

Sept 28 (Reuters) - ABBOTT::ABBOTT SAYS SECURED CE MARK FOR ITS NEXT-GENERATION FREESTYLE LIBRE 3 SYSTEM.ABBOTT SAYS FREESTYLE LIBRE 3 SYSTEM WILL BE PRICED THE SAME AS PREVIOUS GENERATIONS OF THE DEVICE.ABBOTT SAYS LAUNCHING FREESTYLE LIBRE 3 SYSTEM IN COMING MONTHS.  Full Article

Abbott Laboratories- Freestyle Libre 2 Now Available To Medicare Patients
Tuesday, 1 Sep 2020 

Sept 1 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES - NEXT-GENERATION FREESTYLE LIBRE 2 INTEGRATED CONTINUOUS GLUCOSE MONITORING SYSTEM IS NOW AVAILABLE TO MEDICARE PATIENTS.  Full Article

Abbott Receives FDA Approval For Ios-Compatible App Allowing People Living With Chronic Pain And Movement Disorders To Personalize Therapy Via Their Mobile Device
Thursday, 23 Jul 2020 

July 23 (Reuters) - Abbott Laboratories ::ABBOTT RECEIVES FDA APPROVAL FOR IOS-COMPATIBLE APP ALLOWING PEOPLE LIVING WITH CHRONIC PAIN AND MOVEMENT DISORDERS TO PERSONALIZE THERAPY VIA THEIR MOBILE DEVICE.ABBOTT - APPLE‡ SMARTPHONE-COMPATIBLE DIGITAL HEALTH TOOL FITS WITHIN COMPANY'S BROADER NEUROSPHERE DIGITAL CARE CONNECTED CARE MANAGEMENT PLATFORM.ABBOTT LABORATORIES - PATIENT CONTROLLER APP WITH PERSONALIZED ACCESS TO THERAPY WILL BE MADE AVAILABLE STARTING IN COMING WEEKS.  Full Article

Abbott CEO Says "It's Clear That The Need For Testing Is Large And It Isn't Going Away" - Conf Call
Thursday, 16 Jul 2020 

July 16 (Reuters) - Abbott Laboratories ::ABBOTT CEO SAYS AT THE END OF JUNE, PROCEDURE VOLUMES REBOUNDED TO 90% OF PRE-CRISIS LEVELS ON AVERAGE IN U.S. - CONF CALL.ABBOTT CEO SAYS WILL LAUNCH FREESTYLE LIBRE 2 IN THE NEXT FEW WEEKS AT THE SAME PRICE AS THE CURRENT AVAILABLE FREESTYLE LIBRE 14-DAY SYSTEM - CONF CALL.ABBOTT CEO SAYS TESTING VOLUMES IN DIAGNOSTIC BUSINESS EXCLUDING COVID-19 TESTS, REBOUNDED TO ABOUT 90% OF PRE-COVID LEVELS BY END OF Q2 - CONF CALL.ABBOTT IN ADDITION TO MOLECULAR TESTING, ANTICIPATE INCREASED DEMAND FOR OTHER TYPES OF TESTS, INCLUDING BOTH ANTIGEN AND ANTIBODY - CONF CALL.ABBOTT CEO SAYS " IT'S CLEAR THAT THE NEED FOR TESTING IS LARGE AND IT ISN'T GOING AWAY" - CONF CALL.ABBOTT CEO SAYS AS VACCINES BECOME AVAILABLE, ANTICIPATE CONTINUED SURVEILLANCE TESTING TO MONITOR AND ASSESS FOR BOTH NATURAL AND VACCINE-RELATED IMMUNE RESPONSE - CONF CALL.ABBOTT CEO SAYS THE CAPACITY WE ARE BUILDING FOR COVID-19 TESTING IS NOT ONLY FOR A HIGH DEMAND DURING THE NEXT 12-24 MONTHS - CONF CALL.  Full Article

Abbott Reports Second-Quarter Earnings Per Share $0.30 From Continuing Operations
Thursday, 16 Jul 2020 

July 16 (Reuters) - Abbott Laboratories ::REPORTS SECOND-QUARTER 2020 RESULTS, EXCEEDS ANALYSTS' EXPECTATIONS.SEES FY 2020 ADJUSTED EARNINGS PER SHARE AT LEAST $3.25 FROM CONTINUING OPERATIONS EXCLUDING ITEMS.SEES FY 2020 GAAP EARNINGS PER SHARE AT LEAST $2.00 FROM CONTINUING OPERATIONS.Q2 ADJUSTED EARNINGS PER SHARE $0.57 FROM CONTINUING OPERATIONS.Q2 GAAP EARNINGS PER SHARE $0.30 FROM CONTINUING OPERATIONS.Q2 EARNINGS PER SHARE ESTIMATE $0.41 -- REFINITIV IBES DATA.LABORATORIES - PROJECTS FULL-YEAR 2020 DILUTED EPS FROM CONTINUING OPERATIONS ON A GAAP BASIS OF AT LEAST $2.00.LABORATORIES - SEES FULL-YEAR ADJUSTED DILUTED EPS FROM CONTINUING OPERATIONS OF AT LEAST $3.25.LABORATORIES - Q2 WORLDWIDE SALES OF $7.3 BILLION DOWN 8.2% ON REPORTED BASIS & 5.4% ON ORGANIC BASIS, WHICH EXCLUDES IMPACT OF FOREIGN EXCHANGE.LABORATORIES - QUARTERLY MEDICAL DEVICES SALES $2.42 BILLION, DOWN 21.2% ON REPORTED BASIS.IN CORE LABORATORY DIAGNOSTICS, LOWER ROUTINE DIAGNOSTICS TESTING PARTIALLY OFFSET BY SALES OF COVID-19 LABORATORY-BASED TESTS FOR DETECTION OF IGG ANTIBODY IN QUARTER.LABORATORIES QTRLY DIAGNOSTICS SALES $1.99 BILLION, UP 4.7% ON A REPORTED BASIS.LABORATORIES - SAW SIGNIFICANT IMPROVEMENTS IN GROWTH TRENDS THROUGHOUT QUARTER IN BUSINESS AREAS THAT WERE INITIALLY MOST IMPACTED BY PANDEMIC.  Full Article

Abbott Laboratories Files For Potential Debt Shelf Offering
Monday, 22 Jun 2020 

June 22 (Reuters) - Abbott Laboratories ::ABBOTT LABORATORIES SAYS IT FILES FOR POTENTIAL DEBT SHELF OFFERING; SIZE NOT DISCLOSED - SEC FILING.  Full Article

Abbott's Freestyle Libre 2 Cleared In U.S. For Adults And Children With Diabetes
Monday, 15 Jun 2020 

June 15 (Reuters) - Abbott Laboratories ::ABBOTT'S FREESTYLE® LIBRE 2 ICGM CLEARED IN U.S. FOR ADULTS AND CHILDREN WITH DIABETES, ACHIEVING HIGHEST LEVEL OF ACCURACY AND PERFORMANCE STANDARDS.ABBOTT LABORATORIES - WILL OFFER NEW SYSTEM AT SAME PRICE AS CURRENTLY AVAILABLE FREESTYLE LIBRE 14 DAY SYSTEM.ABBOTT- FREESTYLE LIBRE 2 SYSTEM WILL BE AVAILABLE IN COMING WEEKS AT PARTICIPATING PHARMACIES AND DURABLE MEDICAL EQUIPMENT SUPPLIERS ACROSS U.S..ABBOTT - FREESTYLE LIBRE 2 SYSTEM TO BE AVAILABLE IN COMING WEEKS AT PARTICIPATING PHARMACIES, DURABLE MEDICAL EQUIPMENT SUPPLIERS ACROSS U.S..  Full Article

Abbott Declares Quarterly Dividend
Friday, 12 Jun 2020 

June 12 (Reuters) - Abbott Laboratories ::DECLARES 386TH CONSECUTIVE QUARTERLY DIVIDEND.SETS QUARTERLY DIVIDEND OF $0.36PER SHARE.  Full Article

Abbott Receives FDA Emergency Use Authorization For Covid-19 Antibody Blood Test On Alinity™ I System
Monday, 11 May 2020 

Abbott Laboratories ::ABBOTT RECEIVES FDA EMERGENCY USE AUTHORIZATION FOR COVID-19 ANTIBODY BLOOD TEST ON ALINITY™ I SYSTEM.ABBOTT LABORATORIES -.ABBOTT - DATA SHOWS RELIABLE RESULTS WITH 99.6% SPECIFICITY AND 100% SENSITIVITY FOR PATIENTS TESTED 14 DAYS AFTER SYMPTOMS BEGAN.ABBOTT LABORATORIES - ABBOTT PLANS TO SHIP NEARLY 30 MILLION ANTIBODY TESTS GLOBALLY IN MAY ACROSS ITS ARCHITECT AND ALINITY I PLATFORMS.ABBOTT - WILL HAVE CAPACITY TO SHIP 60 MILLION ANTIBODY TESTS IN JUNE.ABBOTT - EXPECTS TO SUBMIT FOR CE MARK FOR ITS ALINITY I SARS-COV-2 IGG TEST THIS WEEK.  Full Article

UPDATE 2-CDC may shorten COVID-19 quarantine period guidelines

Nov 24 The U.S. Centers for Disease Control and Prevention may soon shorten the length of self-quarantine period recommended after potential exposure to the coronavirus, a top official said on Tuesday.